Displaying 2421 - 2440 of 4804
FTC Staff: Proposed Health Care Legislation in West Virginia Would Likely Be Anticompetitive and Harm Consumers
Prepared Statement of the Federal Trade Commission On "Oversight of the Enforcement of the Antitrust Laws"
FTC Chairwoman Ramirez Testifies Before Senate Judiciary Subcommittee on Antitrust, Competition Policy and Consumer Rights
1603001 Informal Interpretation
Quarterly Litigation Status Report- March 2016
FTC Puts Conditions on Drug Manufacturer Hikma Pharmaceuticals PLC’s Proposed Acquisition of Roxane Laboratories Inc. and Boehringer Ingelheim Roxane, Inc. from Boehringer Ingelheim Corporation
FTC Approves Modified Consent Order for Mylan N.V.
Mylan N. V., In the Matter of (Perrigo Company), In the Matter of
Mylan N.V. agreed to sell the rights and assets related to seven generic drugs in order to settle FTC charges that its proposed acquisition of Perrigo Company plc would be substantially reduce competition in the markets for those drugs if the merger proceeded as originally proposed.
1602002 Informal Interpretation
1602001 Informal Interpretation
FTC Requires Drug Marketer Hikma Pharmaceuticals PLC to Divest Rights to Five Generic Injectable Drugs as a Condition of Acquiring Certain Drug Products from Ben Venue Laboratories, Inc.
FTC Puts Conditions on Generic Drug Marketer Lupin Ltd.’s Proposed Acquisition of Gavis Pharmaceuticals LLC
Federal Antitrust Agencies Submit Joint Statement Encouraging Massachusetts to Consider Expanding Treatment Options for Glaucoma Patients
FTC Amicus Brief Urges Appeals Court to Correct District Court Holding that Proving Injury-in-Fact Is Necessary to Establish an Antitrust Violation
In re Nexium (Esomeprazole) Antitrust Litigation
FTC Staff: West Virginia Should Consider the Competitive Impact of Legislation Affecting Advanced Practice Registered Nurses
FTC Submits Fiscal Year 2017 Budget Request, Performance Plan, and Fiscal Year 2015 Performance Report to Congress
Displaying 2421 - 2440 of 4804